首页|依达拉奉右莰醇联合银杏叶提取物对急性脑梗死静脉溶栓术后临床疗效及出血性转化的影响

依达拉奉右莰醇联合银杏叶提取物对急性脑梗死静脉溶栓术后临床疗效及出血性转化的影响

扫码查看
目的 研究依达拉奉右莰醇联合银杏叶提取物对急性脑梗死(ACI)静脉溶栓术后临床疗效及出血性转化的影响.方法 选取2021年10月至2023年4月萍乡市人民医院70例ACI患者,按照随机数字表法分为对照组35例和观察组35例,均行静脉溶栓术治疗;对照组术后应用银杏叶提取物治疗,观察组在对照组基础上联合依达拉奉右莰醇治疗.比较两组治疗前后临床指标进行分析,包括神经功能缺陷及日常活动能力[美国国立卫生研究院卒中量表(NIHSS)、Barthel指数量表],临床疗效,出血性转化发生率,神经功能相关因子水平及治疗后六个月内患者并发症发生情况.结果 观察组治疗后NIHSS评分低于对照组,且日常生活能力评分较高(P<0.05);观察组总有效率高于对照组(P<0.05);观察组出血性转化发生率低于对照组(P<0.05);观察组治疗后中枢神经特异性蛋白(S100-β)、神经元特异性烯醇化酶(NSE)、血管内皮生长因子(VEGF)及人肿瘤坏死因子-α(TNF-α)含量均低于对照组(P<0.05).随访六个月,两组并发症发生率无统计学意义(P>0.05).结论 依达拉奉右莰醇联合银杏叶提取物可以改善ACI静脉溶栓术后患者神经功能缺损症状,提高临床疗效,降低出血性转化发生率,降低S100β、NSE、VEGF及TNF-α水平,从而提高日常生活能力.
The Clinical Efficacy and Hemorrhagic Transformation of Edaravone and Dexborneol Combined with Ginkgo Biloba Extract after Venous Hemolysis in Acute Cerebral Infarction
Objective To investigate the effects of edaravone and dexborneol combined with ginkgo biloba extract on the clinical efficacy and hemorrhagic transformation(HT)of patients after venous hemolysis in acute cerebral infarction(ACI).Methods A total of 70 patients with ACI in Pingxiang People's Hospital from October 2021 to April 2023 were selected and divided into control group(35 cases)and observation group(35 cases)according to random number table method.All patients were treated with venous hemolysis,the control group was treated with ginkgo biloba extract;the observation group were treated with edaravone and dexborneol combined with ginkgo biloba extract.Clinical indicators before and after treatment were compared between the two groups for analysis,including neurological deficits and daily activity ability[National Institutes of Health Stroke Scale(NIHSS)and Barthel index scale],clinical efficacy,incidence of HT,and levels of neurofunction-related factors,and the incidence of complications in patients within six months after treatment.Results After treatment,NIHSS score in observation group was lower than that in control group,and ADL score was higher(P<0.05);the total effective rate of the observation group was higher than that of the control group(P<0.05);the incidence of HT in observation group was lower than that in control group(P<0.05);the contents of S100β,NSE,VEGF and TNF-α in observation group were lower than those in control group(P<0.05).Conclusion Edaravone and dexborneol combined with ginkgo biloba extract can improve the symptoms of neurological impairment in patients after venous hemolysis in ACI,improve clinical efficacy,reduce the incidence of HT,and reduce the levels of S100β,NSE,VEGF and TNF-α,thus improving the ability of daily living.

Edaravone and dexborneolGinkgo biloba extractAcute cerebral infarctionVenous thrombolysisClinical effectHemorrhagic transformation

黄建锋

展开 >

萍乡市人民医院,江西萍乡 337000

依达拉奉右莰醇 银杏叶提取物 急性脑梗死 静脉溶栓 临床疗效 出血性转化

2024

药品评价
江西省药学会

药品评价

影响因子:0.672
ISSN:1672-2809
年,卷(期):2024.21(6)